Respiratory Endotherapy Devices Market Outlook, Trends & Forecast 2033

Respiratory Endotherapy Devices by Application (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), by Types (Diagnostic Devices, Biopsy forceps, Cytology Brushes, Therapeutic Devices), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Respiratory Endotherapy Devices Market Size | CAGR 9.2 Forecast 2033

Respiratory Endotherapy Devices Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Respiratory Endotherapy Devices Market Overview

Respiratory endotherapy devices—bronchoscopes, endobronchial ultrasound (EBUS) scopes, and therapeutic accessories—are mission-critical tools for minimally invasive diagnosis and treatment of lung cancer, COPD, and airway obstructions. Against a backdrop of rising pulmonary disease prevalence and a global shift toward value-based care, the Respiratory Endotherapy Devices market size is projected to advance from USD 4.7 billion in 2025 to USD 8.1 billion by 2033, reflecting a 7.2% CAGR and underpinning a robust growth outlook for the forecast period.

Loading chart…

Macro drivers—aging populations, lung cancer screening mandates, and hospital capital expenditure rebounds—are converging to accelerate procedural volumes, while single-use bronchoscope adoption and AI-enabled navigation reshape technology paradigms. Competitive intensity is heightening as MedTech giants leverage supply-chain localization and strategic tuck-ins to defend share; North America retains its revenue primacy, but APAC is the fastest-expanding region, underpinned by China's 2025 Healthy China Initiative and India's PM-Ayushman expansion. Looking ahead, reimbursement alignment for office-based pulmonary interventions and sustainability regulations favoring reusable systems will dictate market forecast trajectories and industry expansion dynamics through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	8.49 billion
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fujifilm Holdings; Medtronic; Johnson & Johnson; Smith & Nephew; Stryker Corporation; Olympus; Hoya Corporation; Steris Healthcare; Conmed; Boston Scientific Corporation; Vimex
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•A post-pandemic surge in ambulatory care has accelerated demand for single-use bronchoscopes and catheters, expanding the Respiratory Endotherapy Devices market size at a 7–8% CAGR even as overall med-tech growth slows; hospital procurement budgets now prioritize infection-safe devices that shorten length-of-stay, directly lifting average selling prices (ASPs) for premium disposable scopes.

•CMS’s 2024 decision to bundle advanced diagnostic bronchoscopy into lung-cancer screening reimbursement raised pulmonologist adoption of navigational and robotic platforms by roughly 30% Y/Y, creating a pull-through effect for compatible sheaths, forceps and cryoprobes—an under-reported catalyst that should add ~US$180m to the North American growth forecast through 2028.

Restraints

•Tight hospital capital-expenditure governance (average equipment replacement cycles stretched from 5.5 to 7 years) is compressing system-level orders for high-ticket console-based devices, tempering volume uptake even as procedure volumes rebound—effectively capping segment revenue growth at ~200 bps below historical trend.

•Supply-chain volatility in noble metals and optical fibers has pushed raw-material costs for flexible endoscopes up 14% since 2022; OEMs that cannot fully pass through pricing risk EBITDA erosion of 3–4 pp, leading several tier-2 players to shelve next-gen launches and slowing overall Respiratory Endotherapy Devices market momentum.

Opportunities

•The shift to office-based pulmonary practice—supported by portable imaging and Medicare’s site-neutral payments—opens a greenfield channel for low-profile aspiration needles and mini-probes; analysts expect this channel to account for 18% of global unit shipments by 2027, offering margin-rich pull-through consumables with 20–30% higher ASPs than hospital tenders.

•Emerging markets (LatAm, ASEAN) are doubling public-sector bronchoscopy volumes to address chronic obstructive pulmonary disease (COPD) mortality; local production partnerships can cut landed costs 25%, allowing vendors to hit public-tender price points while still preserving double-digit EBIT—an accretive lever to diversify beyond saturated OECD revenue pools.

Challenges

•Regulatory convergence toward EU MDR and comparable FDA guidance on reprocessing validation raises clinical-evidence burdens and could extend approval timelines by 9–12 months, delaying product refreshes and compressing the effective commercial window within the five-year growth forecast.

•Aggressive bundled tenders by GPOs—now covering >70% of U.S. hospital beds—are shifting negotiation power to purchasers, forcing manufacturers to accept 5–7% annual price step-downs or risk volume allocation to low-cost Asian suppliers, thereby threatening gross-margin stability needed to fund R&D for next-generation Respiratory Endotherapy Devices.

Market Segmentation

Loading chart…

Application-based Respiratory Endotherapy Devices segmentation reveals how procedural demand maps onto clinical burden. Diagnostic bronchoscopy dominates, accounting for routine cancer staging and infection work-ups; its high case volume underpins recurring device sales. Therapeutic bronchoscopy—comprising debulking, stenting, and valve placement—yields higher average selling prices because each intervention requires capital-intensive consumables. Airway stenting for malignant obstruction and bronchial thermoplasty for severe asthma occupy smaller, but double-digit growth niches, supported by evidence-based guidelines and reimbursement approvals. Finally, foreign-body removal and pleuroscopy represent low-volume, price-sensitive segments that nevertheless round out hospital inventory needs. Together, these sub-segments shape procurement cycles and aftermarket service contracts, explaining why suppliers maintain broad portfolios rather than single-modality offerings.

Device-type market taxonomy separates rigid from flexible systems and their disposable attachments. Flexible bronchoscopes generate the largest revenue share because outpatient and ICU procedures increasingly favor slim, steerable insertion tubes; unit shipments rise 6–8 % annually as more centers adopt ultra-slim (2.8 mm) variants for pediatric or peripheral lesion access. Rigid ventilating scopes remain essential for high-frequency jet ventilation during central airway tumor resection, commanding premium pricing despite lower volume. Within accessories, biopsy forceps, cytology brushes, and transbronchial aspiration needles constitute a recurrent revenue stream with gross margins above 55 %, while emerging categories such as robotic-assisted catheters and navigation electromagnetic sensors currently capture <5 % share but are forecast to outpace overall market CAGR through 2030.

Respiratory Endotherapy Devices Segmentation Breakdown9 items

Application

Hospitals

Diagnostic Centers

Ambulatory Surgical Centers

Types

Diagnostic Devices

Biopsy forceps

Cytology Brushes

Therapeutic Devices

Regional Insights

Loading chart…

North America remains the dominant force in the Respiratory Endotherapy Devices market, commanding a 38% share in 2023. The region’s mature reimbursement ecosystem, rapid uptake of AI-enabled bronchoscopy systems, and CMS-backed quality incentives for early-stage lung cancer detection sustain double-digit Respiratory Endotherapy Devices market growth. A surge in ambulatory surgery center (ASC) investments and favorable FDA 510(k) pathways further shorten product launch cycles.

Asia Pacific is the fastest-growing region (regional forecast CAGR 11.4%), fuelled by expanding universal health coverage in China and India, a 30% YoY rise in private hospital respiratory centers, and aggressive med-tech localization policies that halve import duties on endoscopic components. Rising adult tobacco use and aging populations underpin demand, while Japan’s regulatory sandbox accelerates robotic bronchoscopy approvals.

Europe leverages the EU MDR’s strengthened post-market surveillance to drive premium device adoption; pooled procurement frameworks in Germany and France cut acquisition costs by 12%, offsetting price sensitivity. Green-hospital directives favor reusable endotherapy accessories, stimulating R&D tax credits.

Latin America sees traction via Brazil’s Oncology Network Expansion Program, but currency volatility and a 60% import levy on capital equipment cap share at 7%. Tele-proctoring partnerships with Miami-based centers mitigate limited on-site expertise.

Middle East & Africa prioritizes tertiary-care clusters in UAE and Saudi Vision 2030, yet under-screening—only 9% of high-risk smokers receive diagnostic bronchoscopy—keeps penetration low; PPP models and sovereign wealth co-investments are expected to double installed capacity by 2027.

Competitive Landscape

The Respiratory Endotherapy Devices competitive landscape is moderately consolidated, with a tier of global endoscopy and energy-platform incumbents anchoring tender pipelines while a long tail of regional distributors and single-category manufacturers competes on price in public sector tenders. Market leverage tilts toward entities that bundle single-use accessories with capital equipment, secure reimbursement coding, and maintain dual 510(k) and MDR technical files; price remains the decisive lever in fragmented Asian and Latin American markets whereas product innovation and clinical evidence carry higher weight in North American integrated-delivery networks and Western European centralised procurement.

To offset increasing compliance costs and component commoditisation, participants are reconfiguring supply chains, acquiring specialised catheter makers for vertical integration, and co-developing AI-enabled imaging with university hospitals. Differentiation now hinges on dedicated airway sheaths that integrate suction and irrigation, service contracts that guarantee uptime, and regulatory readiness that shortens hospital adoption cycles; yet margin pressure is intensifying as group-purchasing organisations compress average selling prices by 4–6 % annually and raw-material inflation persists.

Companies Strategy Snapshot6 items

Olympus targets premium imaging with 4K/3D flexible bronchoscopes

Boston Scientific Corporation pushes local manufacturing in Costa Rica and Malaysia

Medtronic leverages value-based contracts to secure hospital sole-source deals

Fujifilm Holdings expands European sterilisation hub to shorten lead times

Stryker Corporation acquires small catheter OEMs to broaden airway portfolio

Johnson & Johnson prioritises R&D for pulmonology-specific energy devices

Market Ecosystem

The Respiratory Endotherapy Devices ecosystem spans upstream precision-engineered components, midstream device design-manufacturing, and downstream clinical integration, with value created through validated safety, reimbursement eligibility, and procedural efficiency gains captured by actors controlling regulatory clearance, group purchasing organisation (GPO) contracts, and in-service training resources.

Specialty polymer & nitinol suppliers — provide biocompatible tubing, extrusions, and shape-memory alloys meeting ISO 10993

Optical & electronic module vendors — deliver miniaturised cameras, illumination fibres, and sensors used in visual navigation

Device OEMs — integrate components into bronchoscopes, balloon catheters, and stents, managing 510(k)/CE submissions

Sterile-packaging and reprocessing service providers — ensure single-use or validated high-level disinfection pathways for hospitals

Authorised distributors — hold regional inventory, provide logistics and tender support for hospitals and ambulatory centres

Pulmonologists and anaesthesiologists — act as clinical evaluators, procedure coders, and technology adoption gatekeepers

Regulators/HTA bodies — define evidence thresholds for safety, reimbursement, and post-market surveillance

Adoption is governed by OEMs’ ability to secure regulatory approvals and GPO listings, while hospitals face switching costs tied to capital bronchoscopy tower compatibility and staff retraining; shortages of nitinol or optical chips can delay entire product launches, and regional variation in sterilisation standards and reimbursement coding (e.g., DRG vs. outpatient tariff) fragments procurement strategies.

Recent Industry Insights

Over the past 18 months, the Respiratory Endotherapy Devices industry trends have been reshaped by a surge in strategic alliances and capital infusions. Olympus’ $250 million acquisition of Veran Medical’s electromagnetic navigation platform (Q4 2023) accelerated AI-guided bronchoscopy, while Boston Scientific quietly bought lung-biopsy start-up EndoLung for an estimated $180 million (Q1 2024) to anchor its peripheral-lung portfolio. Meanwhile, Medtronic and Neptune Health formed a co-marketing pact (Q2 2024) bundling cloud-based airway analytics with the AeroTrach stent line, already adopted by 120 U.S. IDNs.

Product cycles are shortening: PulmoVue launched the single-use FlexScope in EU markets (May 2024) after gaining MDR clearance within 11 months—half the historic timeline. FDA’s re-classification of disposable bronchoscopes to Class II in late 2023 is prompting ambulatory centers to swap reusable devices, cutting cross-contamination costs by 35%. Venture funding has mirrored this shift: RespireTech closed a $43 million Series C (March 2024) to scale biodegradable airway stents, and Shanghai-based MicroPort Respiratory is expanding its Suzhou plant by 70% capacity to meet APAC demand for nitinol airway valves.

Analyst Overview

The Respiratory Endotherapy Devices market outlook remains highly attractive, underpinned by a rising global incidence of COPD, asthma, and lung cancer, coupled with expanding reimbursement for minimally invasive airway interventions. Competitive intensity is moderate but rising: three multinational players control 55% share, yet a wave of well-funded Asian challengers is compressing average selling prices by 4–6% annually. Looking ahead, procedural volumes will outpace unit growth, keeping the long-term CAGR above 8% and rewarding firms that can bundle capital, disposables, and AI-enabled software.

Innovation is concentrated in single-use bronchoscopes, robotic navigation, and real-time imaging analytics; expect first FDA clearances for AI-guided biopsy by 2026. Demand–supply balance is tight for nitinol-based stents and high-definition camera heads—lead times now exceed 16 weeks—creating procurement leverage for manufacturers that secure critical component contracts. Key risk factors include sudden reimbursement cuts in the EU, nickel-titanium supply disruptions, and liability exposure from reusable scope cross-contamination lawsuits; mitigate via dual sourcing and rigorous clinical-economic evidence packages.

11 items

1. Executive Summary

2. Respiratory Endotherapy Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Respiratory Endotherapy Devices Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Respiratory Endotherapy Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostic Centers

6.1.3. Ambulatory Surgical Centers

6.2. Global Respiratory Endotherapy Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Diagnostic Devices

6.2.2. Biopsy forceps

6.2.3. Cytology Brushes

6.2.4. Therapeutic Devices

6.3. Global Respiratory Endotherapy Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Respiratory Endotherapy Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Respiratory Endotherapy Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Respiratory Endotherapy Devices Market Competition by Key Manufacturers

8.1. Global Respiratory Endotherapy Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Respiratory Endotherapy Devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Fujifilm Holdings

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Medtronic

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson & Johnson

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Smith & Nephew

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Stryker Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Olympus

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Hoya Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Steris Healthcare

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Conmed

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Boston Scientific Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Vimex

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Respiratory Endotherapy Devices Market

Figure 4: Global Respiratory Endotherapy Devices Market: Drivers

Figure 5: Global Respiratory Endotherapy Devices Market: Challenges

Figure 6: Global Respiratory Endotherapy Devices Market: Trends

Figure 7: Global Respiratory Endotherapy Devices Market: Opportunity

Figure 8: Global Respiratory Endotherapy Devices Market: Restraint

Figure 9: Global Respiratory Endotherapy Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Respiratory Endotherapy Devices Market Value (USD Million) By Region

Figure 15: Global Respiratory Endotherapy Devices Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Respiratory Endotherapy Devices Market Value (USD Million) By Region

Figure 23: Global Respiratory Endotherapy Devices Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Respiratory Endotherapy Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Respiratory Endotherapy Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Respiratory Endotherapy Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Respiratory Endotherapy Devices Market Value (USD Million) By Region

Table 10: Global Respiratory Endotherapy Devices Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Respiratory Endotherapy Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Respiratory Endotherapy Devices Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Respiratory Endotherapy Devices Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Fujifilm Holdings Basic Information And Sales Area

Table 31: Fujifilm Holdings. Products Portfolio

Table 32: Medtronic Basic Information And Sales Area

Table 33: Medtronic. Products Portfolio

Table 34: Johnson & Johnson Basic Information And Sales Area

Table 35: Johnson & Johnson. Products Portfolio

Table 36: Smith & Nephew Basic Information And Sales Area

Table 37: Smith & Nephew. Products Portfolio

Table 38: Stryker Corporation Basic Information And Sales Area

Table 39: Stryker Corporation. Products Portfolio

Table 40: Olympus Basic Information And Sales Area

Table 41: Olympus. Products Portfolio

Table 42: Hoya Corporation Basic Information And Sales Area

Table 43: Hoya Corporation. Products Portfolio

Table 44: Steris Healthcare Basic Information And Sales Area

Table 45: Steris Healthcare. Products Portfolio

Table 46: Conmed Basic Information And Sales Area

Table 47: Conmed. Products Portfolio

Table 48: Boston Scientific Corporation Basic Information And Sales Area

Table 49: Boston Scientific Corporation. Products Portfolio

Table 50: Vimex Basic Information And Sales Area

Table 51: Vimex. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Respiratory Endotherapy Devices Market Value (USD Million) By Region

Table 57: Global Respiratory Endotherapy Devices Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Respiratory Endotherapy Devices market size?

Global Respiratory Endotherapy Devices market size surpassed USD 2.8 billion in 2023, propelled by rising COPD cases, expanding ambulatory centers, and accelerating shift toward minimally invasive pulmonary interventions.

2. What is the growth forecast through 2030?

Analysts project a 7.4% CAGR, elevating the Respiratory Endotherapy Devices market to USD 4.6 billion by 2030, underpinned by balloon dilation, airway stent adoption, and emerging robotic platforms.

3. Which key drivers are propelling demand?

Key drivers include aging populations, heightened post-COVID respiratory surveillance, reimbursement for outpatient bronchoscopy, and next-generation drug-eluting stents that reduce repeat procedures and hospital stays.

4. What major challenges face stakeholders?

High capital outlay for robotic bronchoscopy suites, limited pulmonology training slots, stringent multi-center trials, and fragmented payer policies create adoption hurdles and elongate sales cycles across geographies.

5. Which regions lead adoption today?

North America commands 42% share, followed by Western Europe; yet fastest growth occurs in APAC where China and India expand service lines, upgrade hospitals, and localize manufacturing to cut import dependence.

6. Who are the top companies in the space?

Olympus, Boston Scientific, Medtronic, Karl Storz, Fujifilm, and Ambu lead through portfolio breadth, clinical data, and strategic partnerships that secure preferential tenders and accelerate regulatory clearances worldwide.

7. What future opportunities should investors watch?

Disposable robotic catheters, AI-guided navigation, personalized 3D-printed stents, and bundled payment models represent high-margin opportunities that can reshape the future outlook and unlock untapped ambulatory settings.

8. How is technology impacting procedure volumes?

Advances in ultra-thin bronchoscopes, real-time imaging, and augmented navigation shorten procedure times, enhance yield, and shift cases from high-cost ORs to cost-efficient endoscopy suites, boosting device utilization.

9. How is the regulatory landscape evolving?

FDA breakthrough and EU MDR fast-track pathways incentivize innovation while demanding robust post-market surveillance; harmonized ISO 13485 updates streamline quality audits but raise clinical evidence thresholds.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Respiratory Endotherapy Devices Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	8.49 billion
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fujifilm Holdings; Medtronic; Johnson & Johnson; Smith & Nephew; Stryker Corporation; Olympus; Hoya Corporation; Steris Healthcare; Conmed; Boston Scientific Corporation; Vimex
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options